Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Balo's Concentric Sclerosis”

5 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 5 of 5 results

Large-scale testing (Phase 3)Ended earlyNCT04378075
What this trial is testing

Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy

Who this might be right for
Mitochondrial DiseasesDrug Resistant EpilepsyLeigh Disease+5 more
PTC Therapeutics 68
Not applicableEnded earlyNCT03034512
What this trial is testing

Alpers Huttenlocher Natural History Study

Who this might be right for
Alpers Huttenlocher Syndrome
Columbia University 2
Large-scale testing (Phase 3)Study completedNCT05218655
What this trial is testing

A Safety Study for Previously Treated Vatiquinone (PTC743) Participants With Inherited Mitochondrial Disease

Who this might be right for
Inherited Mitochondrial Disease
PTC Therapeutics 101
Large-scale testing (Phase 3)UnknownNCT00004645
What this trial is testing

Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous Methylprednisolone

Who this might be right for
Acute Disseminated EncephalomyelitisDevic's SyndromeMarburg's Variant of Multiple Sclerosis+2 more
National Institute of Neurological Disorders and Stroke (NINDS) 22
Testing effectiveness (Phase 2)Study completedNCT00879658
What this trial is testing

Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis

Who this might be right for
Relapsing-remitting Multiple Sclerosis
Novartis Pharmaceuticals 297